TherapeuticsMD
TXMD
56 hedge funds and large institutions have $362M invested in TherapeuticsMD in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 12 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
81% more capital invested
Capital invested by funds: $200M → $362M (+$162M)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
6% more funds holding
Funds holding: 53 → 56 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.08% less ownership
Funds ownership: 1.04% → 0.96% (-0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$18.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.88M |
| 3 |
VM
VHCP Management
New York
|
+$3.71M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.66M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$21.3M |
| 2 |
DM
Deerfield Management
New York
|
-$3.66M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.54M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.22M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$332K |
TXMD Hedge Fund Activity: Q4 2013 in Review
56 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2013, worth a combined $362M — up 81% from $200M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TXMD positions and 12 closed out — a net gain of 3 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $18.7M. The largest seller was RA Capital Management, cutting an estimated $21.3M.
- 56 institutional investors held TherapeuticsMD (TXMD) as of Q4 2013, up from 53 in Q3 2013.
- Funds reported $362M of TherapeuticsMD stock for Q4 2013, up 81% quarter-over-quarter.
- 15 funds opened new TherapeuticsMD positions in Q4 2013 and 12 closed out, a net change of +3 holders.
- The largest TherapeuticsMD buyer in Q4 2013 was Gilder Gagnon Howe & Co, an estimated $18.7M added.
- The largest TherapeuticsMD seller in Q4 2013 was RA Capital Management, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2013.